Monday, June 4, 2012

History of Artemisinin

Artemisia annua has been used by Chinese herbalists for more than two thousand years in the treatment of many illnesses, such as skin diseases and malaria. The earliest record dates back to 200 BC, in the "Fifty-two Prescriptions" unearthed from the Mawangdui Han Dynasty tombs. Its antimalarial application was first described, in Zhouhou Beiji Fang ("The Handbook of Prescriptions for Emergencies"), edited in the middle of the fourth century by Ge Hong. In that book, 43 malaria treatment methods were recorded.

 artemisinin In the 1960s, a research program, under the name Project 523, was set up by the Chinese army to find an adequate treatment for malaria. In 1972, in the course of this research, Tu Youyou discovered artemisinin in the leaves of Artemisia annua (annual wormwood). The drug is named Qinghaosu (Chinese: 青蒿素) in Chinese. It was one of many candidates then tested by Chinese scientists from a list of nearly 5000 traditional Chinese medicines for treating malaria. It was not only the only one that was effective, but it was found to clear malaria parasites from patients' bodies faster than any other drug in history. Artemisia annua is a common herb and has been found in many parts of the world, including along the Potomac River, in Washington, D.C. Images of the original scientific papers are available online and a book, Zhang Jianfang, "Late Report – Record of Project 523 and the Research and Development of Qinghaosu", Yangcheng Evening News Publisher 2007 was published in 2006, which records the history of the discovery.
It remained largely unknown to the rest of the world for about seven years, until results were published in the Chinese Medical Journal in 1979. The report was met with skepticism at first, partly because the chemical structure of artemisinin, particularly the peroxide, appeared to be too unstable to be a viable drug.
For many years after the discovery, access to the purified drug and the plant from which it was extracted were restricted by the Chinese government. It was not until the late 1970s and early 80s that news of the discovery reached scientists outside China. The World Health Organisation (WHO) tried to contact Chinese scientists and officials to find out more, but drew a blank. Ying Lee, one of the scientists involved in the research into artemisinin, said the Chinese distrusted the West. The Chinese suspected the West just wanted to exploit the drug and sell it around the world slightly altered and repatented. The fact that there were several Americans on the WHO's steering board on malaria and that some were from the military did not help clear the distrust. It can be noted Americans had just invested a lot into mefloquine, an analogue of quinine.

In 2006, after artemisinin had become the treatment of choice for malaria, the WHO called for an immediate halt to single-drug artemisinin preparations in favor of combinations of artemisinin with another malaria drug, to reduce the risk of parasites developing resistance.

In 2011, Tu was awarded the prestigious Lasker-DeBakey Clinical Medical Research Award for her discovery. The discovery of artemisinin is reportedly being considered for a Nobel Prize in Medicine.

Project 523 developed, in addition to artemisinin, a number of products that are used in combination with artemisinin, including lumefantrine, piperaquine, and pyronaridine.

Read More: artemisinin price

Introduction of 9-Fluorenone

 9-Fluorenone





Item name: 9-Fluorenone
CAS No.: 486-25-9
Purity(HPLC): 99%min (GC)
Appearance: Yellow crystal powder
Boiling point: 341.5 ℃
Melting point: 82-85℃
Application: It is mainly used for making synthetic resins, dyes, pesticides, preservatives, etc.

Fluorenone (9-fluorenone) is an aromatic organic compound with the chemical formula C13H8O. It is used to make antimalaria drugs.

Fluorenone can be produced from fluorene via oxidation (by common oxidizers or even atmospheric oxygen).

Details of GRF (Human) Acetate


Growth-hormone-releasing hormone (GHRH), also known as growth-hormone-releasing factor (GRF, GHRF), somatoliberin or somatocrinin, is a releasing hormone for growth hormone. It is a 44-amino acid peptide hormone produced in the arcuate nucleus of the hypothalamus.

GHRH first appears in the human hypothalamus between 18 and 29 weeks of gestation, which corresponds to the start of production of growth hormone and other somatotropes in fetuses.

Molecular Formula: C215H358N72O66S
CAS No.: 83930-13-6
Sequence:
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-            Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2

Details of GRF (Human) Acetate:
Purity (HPLC)                                   98%min.
Appearance                                White powder
Single Impurity (HPLC)                1.0%max
Amino Acid Composition             ±10% of theoretical
Peptide Content (N%)                   ≥80.0%
Water Content (Karl Fischer)       ≤6.0%
Acetate Content (HPIC)                  ≤15.0%
MS (ESI)                                        Consistent
Mass Balance                                95.0~105.0%

Read More: GRF (human) Acetate price

Basic Description of Bifidobacterium Bifidum










Bifidobacterium is a genus of Gram-positive, non-motile, often branched anaerobic bacteria. They are ubiquitous, endosymbiotic inhabitants of the gastrointestinal tract, vagina and mouth (B. dentium) of mammals and other animals. Bifidobacteria are one of the major genera of bacteria that make up the colon flora in mammals. Some bifidobacteria are used as probiotics.

Bifidobacterium bifidum is a probiotic, or a beneficial kind of bacteria. Probiotics live inside the body, mainly in the gastrointestinal system. These good bacteria promote healthy digestion, strengthen the immune system, and work to eliminate harmful and unhealthy bacteria from the body. Low levels of probiotics in the intestines can result in many unpleasant symptoms such as abdominal bloating and cramps, yeast infections, and food sensitivities. Bifidobacterium bifidum can be added to the diet through the use of supplements or the consumption of yogurt containing live culture.

Read More: Bifidobacterium bifidum suppliers

Simple Knowledge About SIL-18 ELISA Kit

 sIL-18 ELISA Kit


Product name: sIL-18 ELISA Kit
Specification :96Test
Serum IL-18 (SIL-18) on both days 1 and 7 was significantly higher in both post-stroke depression patients and non-post-stroke depression patients than in normal controls. Serum IL-18 on day 7 was significantly higher in post-stroke depression patients than in non-post-stroke depression patients. Serum IL-18>377.84 pg/ml on day 7 was independently associated with incident post-stroke depression at the acute stage of stroke (odds ratio: 12.280, 95% confidence interval: 3.848-39.190, p<0.001 after adjustment). At 6 months, 31 patients (33.0%) were diagnosed with major depression. Serum IL-18 >376.67 pg/ml on day 7 was independently associated with post-stroke depression at 6 months (odds ratio: 7.431, 95% confidence interval: 1.741-31.712, p=0.007 after adjustment). Conclusions: Serum IL-18 on day 7 after admission may predict the risk of post-stroke depression both at the acute stage of stroke and at 6 months post-stroke.

Read More: buy SIL-18 ELISA Kit

Detailed Knowledge About SCGF-a ELISA Kit


A method for producing a hematopoietic stem cell growth factor (SCGF) polypeptide having erythroid burst-promoting activity and granulocyte macrophage colony-promoting activity on bone marrow cells of a mammal, comprising culturing the transformant of claim 26 in a medium that promotes the production and accumulation of the polypeptide and recovering the polypeptide from the resultant culture.

Item name: SCGF-a ELISA Kit
Specification: 96Test

 SCGF-a ELISA Kit The present invention relates to a novel hematopoietic growth factor protein termed hematopoietic stem cell growth factor (hereinafter referred to as “SCGF”) which acts on hematopoietic stem cells to maintain their survival and to induce their proliferation and differentiation. The present invention also relates to a gene coding for SCGF; a vector comprising the gene; a transformant transformed with the vector; a method for producing SCGF; and a method for separating and purifying SCGF. The present invention further relates to the use of SCGF as a therapeutic for hematopoietic insufficiency derived from irradiation or chemotherapy for patients with various hematopoietic diseases or cancers; or the use of SCGF as a reagent for diagnostic analysis. The present invention also relates to the use of SCGF in bone marrow transplantation for the purpose of hematopoietic recovery, for which hematopoietic stem cells can be amplified with SCGF in vitro in a small amount of bone marrow aspirates; and the use of SCGF in gene therapy to improve the efficiency of a gene transfer into hematopoietic stem cells. The invention also relates to a vector developed to isolate the SCGF gene, as well as a method for isolating the gene. The vector and the method can provide promising tools to search for other novel genes for unknown proteins.
Read More: SCGF-a ELISA Kit for sale

Properties of Chlorotrifluoroethylene


Item Name: Chlorotrifluoroethylene
Molecular Formula: C2ClF3
CAS No.: 79-38-9
Properties of Chlorotrifluoroethylene:
mw   116.47
mp  −158 °C(lit.)
bp  −28.4 °C(lit.)
density  1,305 g/cm3
vapor density  4.13 (vs air)
Fp  -28°C

CTFE, or chlorotrifluoroethylene is a chlorofluorocarbon with chemical formula CF2CClF. It is commonly used as a refrigerant in cryogenic applications. CTFE has a C=C double bond and so can be copolymerised to produce the plastic ECTFE. CTFE has also been polymerized into the homopolymer PCTFE meaning polychlorotrifluoroethylene. PCTFE has the trade name Neoflon® from Daikin Industries in Japan, and used to be produced under the trade name Kel-F® from 3M Corporation in Minnesota.


Read More: Chlorotrifluoroethylene price